Novo to share real-world and clinical data in...

Novo Nordisk will present 44 new cardiometabolic studies at EASD 2026 in Milan.

What the company is saying

Novo Nordisk is announcing its scientific agenda for the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026, highlighting 44 abstracts covering semaglutide, CagriSema, zenagamtide, and other pipeline assets. The company frames this as evidence of its leadership in cardiometabolic innovation, emphasizing the breadth of its research across obesity, type 2 diabetes, cardiovascular, kidney, and liver diseases. Martin Holst Lange, executive vice president of Research & Development and chief scientific officer, is quoted to reinforce the ambition to shape the next generation of cardiometabolic care. The announcement stresses real-world and clinical data, including the OCTANE study on Wegovy® pill, CagriSema's impact on appetite and body composition, and new phase 2b results for zenagamtide. Novo Nordisk also draws attention to the global diabetes burden—589 million adults today, projected to reach 853 million by 2050, with 3.4 million deaths in 2024—and its scale, with over 67,000 employees worldwide. The tone is confident, focusing on scientific leadership and unmet medical need, but does not disclose new topline clinical results or financial performance.

What the data suggests

The company will present 44 abstracts at EASD 2026, with topics spanning semaglutide, CagriSema, zenagamtide, and other pipeline assets. Named studies include OCTANE (real-world Wegovy® pill use), REIMAGINE 1 (CagriSema in early type 2 diabetes), REDEFINE 1 (cagrilintide 2.4 mg), and phase 2b results for zenagamtide. Real-world evidence from China will be included, focusing on semaglutide’s impact on cardiovascular and renal events. The announcement quantifies the global diabetes burden: 589 million adults affected, projected to rise to 853 million by 2050, and 3.4 million deaths in 2024. Novo Nordisk employs over 67,000 people globally. No new clinical efficacy, safety, or financial results are disclosed; the release is limited to outlining the scope and agenda of the upcoming conference presentations. The evidence supports the company’s scientific engagement but does not provide new data to assess business or clinical progress.

Analysis

The announcement is upbeat, emphasizing Novo Nordisk's broad scientific presence at EASD 2026 and the potential impact of its pipeline. However, the substance is limited to the planned presentation of 44 abstracts, with no new topline clinical results, financial data, or operational milestones disclosed. Most claims are factual (scheduled presentations, study names, and topics), but the headline quote about 'shaping the next generation of cardiometabolic care' is aspirational and not yet supported by disclosed outcomes. The forward-looking language is promotional but not extreme, as it is typical for conference previews. There is no evidence of a large capital outlay or immediate financial impact. The gap between narrative and evidence is moderate: the company highlights potential and ambition, but the only realised facts are the upcoming presentations and study topics.

Risk flags

• ●There is a risk that the actual data presented at EASD 2026 may not meet investor or market expectations, as the announcement does not preview topline clinical results or headline-making outcomes. This could lead to disappointment if the studies are incremental rather than transformative.
• ●The announcement relies on broad claims about shaping the next generation of cardiometabolic care without providing supporting clinical or financial evidence. This creates a gap between the aspirational narrative and the realised facts, which may raise questions about the materiality of the news.
• ●The company highlights the scale of the diabetes epidemic and its own workforce, but does not connect these figures to specific business outcomes or pipeline advancement. Without new efficacy, safety, or commercial data, the practical impact for shareholders remains uncertain.

Bottom line

Novo Nordisk is using its presence at EASD 2026 to reinforce its leadership in cardiometabolic research, with 44 abstracts covering key pipeline assets and real-world studies. The announcement is a scientific agenda preview, not a disclosure of new clinical or financial results. While the breadth of studies and the company’s global scale are impressive, no new data is provided to change the investment case or clarify near-term business catalysts. The most important takeaway is that the real value for investors will come from the actual content and reception of these presentations, not from this preview. Investors should focus on the outcomes and details released during or after EASD 2026 to assess any material impact. Until then, this update is informative but not actionable.

Announcement summary

(LSE/AIM:0QIU) Novo Nordisk announced it will present new data from its cardiometabolic pipeline and portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The company will share 44 abstracts, including data on semaglutide, CagriSema, and zenagamtide, covering obesity, type 2 diabetes, cardiovascular, kidney, and liver-related outcomes. Key presentations include real-world evidence on Wegovy® pill use in adults with overweight or obesity, CagriSema data on appetite regulation and body composition, and studies on semaglutide's effects on liver fat and cardiovascular events. The OCTANE study will provide insights into Wegovy® pill use, including weight outcomes, treatment switching, and patient-reported outcomes. Presentations will also cover the efficacy of CagriSema on body composition in early type 2 diabetes (REIMAGINE 1), the impact of cagrilintide 2.4 mg on physical function (REDEFINE 1), and phase 2b results for zenagamtide in type 2 diabetes. Additional data will be presented on Ozempic® 2.0 mg, including cardiovascular event comparisons and pharmacometric modelling for dose escalation. Real-world evidence from China will be shared on semaglutide's impact on cardiovascular and renal events in type 2 diabetes patients, including combination therapy with SGLT2i. UBT251, a triple hormone receptor agonist, will be discussed in phase 2 trials for obesity and type 2 diabetes. Insulin icodec and IcoSema studies will be presented, focusing on continuous glucose monitoring and hypoglycaemia outcomes. The company highlighted that 589 million adults (20-79 years) are living with diabetes, a figure projected to rise to 853 million by 2050, and that diabetes caused 3.4 million deaths in 2024. Novo Nordisk employs over 67,000 people worldwide. Martin Holst Lange, executive vice president of Research & Development and chief scientific officer, stated that the findings have the potential to shape the next generation of cardiometabolic care. The company will host an International Press Briefing on 30 September 2026 during EASD in Milan, accessible via webcast.

Disagree with this article?